All News

The FDA approved Imfinzi with chemotherapy for adults with resectable gastric or gastroesophageal junction adenocarcinoma.

Surviving breast cancer changes the way you see your body. Every ache, every spot, every unfamiliar sensation becomes a quiet question: “Could it be coming back?”

From diagnosis to treatment, here is what patients need to know about squamous cell carcinoma of the bladder.

The FDA granted fast track designation to AVZO-103 for the treatment of patients with previously treated locally advanced or metastatic urothelial cancer.

An expert explains how minimally invasive surgery helps remove smaller lung areas with quicker recovery and improves outcomes for patients with early-stage lung cancer.

I share how the holidays feel different after loss and how grief, love and gratitude can coexist as I navigate this season with gentleness and care.

Dr. Charles M. Rudin highlights T cell engagers, antibody-drug conjugates and emerging strategies showing early benefits for small cell lung cancer.

The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients with polycythemia vera.

Voranigo was safe and well tolerated in patients with grade 3 or 4 IDH-mutant gliomas, a type of brain cancer.

Imbruvica plus R-MPV led to high response rates and was tolerable for patients with newly diagnosed primary central nervous system lymphoma.

Dr. Pamela L. Kunz sat down for an interview with CURE to discuss resources and ongoing initiatives that may help patients with this disease.

Eflornithine plus Gleostine was associated with superior overall survival and progression-free survival in grade 3 IDH-mutated astrocytoma.

Intraventricular B7-H3 CAR T-cell therapy was well tolerated up to 1 x 10⁷ cells per infusion and showed early signs of activity in recurrent glioblastoma.

Voranigo plus Temodar was safe in glioma with IDH1/2 mutations.

Early data from the SJ901 study show Gomekli generates responses with manageable side effects in children and young adults with low grade glioma.

Early data indicate Voranigo is rapidly being used in newly diagnosed and previously treated patients with IDH-mutant glioma, highlighting ongoing treatment needs.

Researchers identified a potential unmet need for an effective early treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive cisplatin after surgery.

In a recent interview with CURE, Nona Baker shared insights from her blood cancer journey that began more than 30 years ago.

Giredestrant improved invasive disease-free survival for people with estrogen receptor-positive early breast cancer compared with standard treatment.

I share how the nurses who cared for my daughter during chemotherapy brought comfort, connection and humanity that carried us through our hardest moments.

Immune-based therapies are transforming advanced liver cancer care, resulting in curative options previously considered unattainable.

Nona Baker received a diagnosis of essential thrombocythemia in 1991, followed by polycythemia vera in 2004.

Dr. Anne Chiang explains how biomarker testing and molecular profiling personalize lung cancer treatment and compare tissue versus liquid biopsies.

After surviving testicular cancer, I feel like I was given a second chance at life. Although given challenges, I have learned to be resilient and face adversity head-on.

Dr. Ajay Gupta sat down with CURE to explain the basics of gastrointestinal stromal tumors, highlighting what patients with this disease need to know.

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive non-small cell lung cancer.

Dr. Michael Staehler highlighted nutrition’s role in kidney cancer, noting that diet, stress management, and lifestyle can impact outcomes and well-being.